KUBR

SEC finds Valeant improperly recognised Philidor revenue; $45m company penalty

Valeant Pharmaceuticals International, Inc. (Bausch Health) · Pharmaceuticals

Revenue inflationRelated-party diversionRegulatory breachGovernance failure

The case in brief

Visible before detection

    Checks that could have surfaced it, on hindsight

    1

    Ownership / related-party links

    Would have mapped Philidor's ownership and control links to Valeant.

    Can mislead when: Nominee directors and offshore layers hide links. Name matching throws up false positives, so every flag shows its evidence path.

    2

    Operating-metric verification

    Would have tested organic growth claims against underlying prescription data.

    Can mislead when: Contract staff do not appear in EPFO. Vahan access needs licensed APIs. Some businesses have no physical trace.

    3

    Bank credits vs books

    Would have compared reported revenue to cash from independent end customers.

    Can mislead when: AA only sees the accounts the company links, so an undisclosed account stays invisible. Cash-heavy businesses and timing differences create false flags.

    4

    Regulatory & litigation records

    Would have surfaced press and short-seller scrutiny of Philidor.

    Can mislead when: Court records lag and name spellings vary. A clean record can mean the problem has not reached court yet.

    Where Kubr services would have helped

    Portfolio monitor

    Offered in India
    • C1 Would have compared reported revenue to cash from independent end customers.
    • C3 Would have mapped Philidor's ownership and control links to Valeant.
    • C8 Would have surfaced press and short-seller scrutiny of Philidor.
    • C10 Would have tested organic growth claims against underlying prescription data.

    Financial diligence

    Offered in India
    • C1 Would have compared reported revenue to cash from independent end customers.
    • C3 Would have mapped Philidor's ownership and control links to Valeant.
    • C10 Would have tested organic growth claims against underlying prescription data.

    Valuation context

    Offered in India
    • C8 Would have surfaced press and short-seller scrutiny of Philidor.

    Borrower monitor

    Offered in India
    • C1 Would have compared reported revenue to cash from independent end customers.
    • C3 Would have mapped Philidor's ownership and control links to Valeant.
    • C8 Would have surfaced press and short-seller scrutiny of Philidor.

    Mapped from the checks each service runs. A hindsight reading of public records, not a promise that the failure would have been found.

    A summary of public documents. It reports what the sources say. It is not Kubr's finding and not a statement of guilt.